Rebastinib

Generic Name
Rebastinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C30H28FN7O3
CAS Number
1020172-07-9
Unique Ingredient Identifier
75017Q6I97
Background

Rebastinib has been used in trials studying the treatment of Chronic Myeloid Leukemia. It is an inhibitor of Tie2 tyrosine kinase receptor and an antineoplastic agent.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

First Posted Date
2018-10-24
Last Posted Date
2024-01-18
Lead Sponsor
Deciphera Pharmaceuticals, LLC
Target Recruit Count
117
Registration Number
NCT03717415
Locations
๐Ÿ‡บ๐Ÿ‡ธ

The Ohio State University, Columbus, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Chicago, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

MD Anderson Cancer Center, Houston, Texas, United States

and more 6 locations

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

First Posted Date
2018-07-26
Last Posted Date
2023-09-21
Lead Sponsor
Deciphera Pharmaceuticals, LLC
Target Recruit Count
177
Registration Number
NCT03601897
Locations
๐Ÿ‡บ๐Ÿ‡ธ

The University of Kansas Clinical Research Center, Kansas City, Kansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Ohio State University Wexner Medical Center, Columbus, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

and more 11 locations

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

First Posted Date
2016-07-06
Last Posted Date
2022-04-04
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
28
Registration Number
NCT02824575
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Montefiore Medical Center, Bronx, New York, United States

ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy